Does NEOG pay a dividend and is it safe?

Neogen Corporation (NEOG) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / NEOG / dividends

CLDX (29) NTLA (25) ORKA (53) LNTH (76) ⌘ Pro Terminal →

Neogen Corporation (NEOG) Dividend Safety Gauge & 10-Year DRIP Compounder

$11.82 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $11.80

Neogen Corporation (NEOG) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $2.58B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NEOG Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NEOG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Neogen Corporation (NASDAQ: NEOG) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $11.82 (0.00% 1D, market cap $2.58B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 8/20. Across 1015 tracked Health Care issuers, NEOG ranks #301 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NEOG compare to CLDX and NTLA in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), NEOG carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of 46.9%, and ROIC of -0.6%. By comparison, CLDX (Celldex Therapeutics Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $2.36B) and NTLA (Intellia Therapeutics Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $1.75B). Among the 5-stock peer group, LNTH leads on earnings multiple (28.0x) while LNTH leads on capital efficiency (20.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NEOG?

▼

Per NEOG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-05-31, CIK 0000711377), Neogen Corporation generated $870.4M in revenue (-2.7% YoY), -$7.9M in net income, and $83.2M in free cash flow against $3.36B in total assets and $792.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $11.80 (-0.19%)🧬 Disciplined Float (-0.12% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 9.6% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NEOG)Realized 20D OHLCV Swing Band: ±9.7%

Deterministic 5-Pillar Attribution (47/100 Composite)

🔍 WHY NEOG SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+12/20 pts (26% of score)

FRED Regime × Technicals: 73% of 52W Range • RSI-14 at 45.9 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+10/20 pts (21% of score)

20D Institutional Volume Accumulation (±9.7% realized swing band)

▼ #1 Drag / Risk Factor: Cash Engine Quality7/20 pts (-13 pt drag)

Capital intensity & 0% operating margin leave 13 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$11.73-0.1% Next Q

Q2 (-2Q)

Grade D$11.72+6.4% Next Q

Q3 (-1Q)

Grade D$12.47-5.2% Next Q

Current

Grade D$11.82-5.9% Hist 90D α

Trajectory: E (39) → D (47)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NEOG Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NEOG currently carries a cautious 47/100 (D) rating due to Cash Engine Quality (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.24) and Max Pain ($12.41) forces dealer call-delta covering toward $14.97.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.12% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NEOG• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NEOG Beats Next Quarter EPS Consensus (Nov 29, 2026) & Holds Above 200D SMA”

YES 47%NO 53%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $307/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NEOG)

✓Walkthrough of NEOG's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NEOG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +30.03%▲ ASCENDING CHANNEL

2026-11-03O $12.26H $12.26L $11.82C $11.82VOL 1.95M

RES: $15.40SUP: $10.26SMA50: $12.24SMA200: $10.45

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NEOG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NEOG Butterfly Map → + Track NEOG →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -2.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NEOG today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NEOG. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NEOG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NEOG)

Health Care Rank #301 of 1015 ⚔️ CLDX vs NEOG Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NEOG vs. CLDX, NTLA, ORKA, LNTH)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Neogen Corporation (NEOG) ranks #301 by composite RQD confidence (47/100, grade D) and #216 by equity capitalization ($2.58B). Within this direct 5-issuer industry benchmark cohort, LNTH leads on earnings valuation at 28.0x trailing P/E, while LNTH leads on capital efficiency and profitability with 20.3% ROIC and 61.1% gross margin. LNTH currently holds the highest overall quantitative score in the immediate peer group at 76/100 (B+) compared with NEOG at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NEOG ACTIVE Neogen Corporation	D	47/100	—	46.9%	-0.6%	0.00%	$2.58B	Benchmark Subject
CLDX Celldex Therapeutics Inc.	E	29/100	—	87.1%	-35.0%	-3.52%	$2.36B	/cldx-vs-neog →
NTLA Intellia Therapeutics Inc.	E	25/100	—	—	-35.0%	-6.50%	$1.75B	/ntla-vs-neog →
ORKA Oruka Therapeutics Inc.	D+	53/100	—	—	-18.8%	-1.49%	$6.41B	/orka-vs-neog →
LNTH Lantheus Holdings Inc.	B+	76/100	28.0x	61.1%	20.3%	-0.15%	$6.56B	/lnth-vs-neog →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-05-31 • CIK 0000711377 ↗

In its most recent audited fiscal period (FY2025, filed 2026-05-31), Neogen Corporation (NEOG) reported GAAP revenue of $870.4M (-2.7% vs. FY2024 revenue of $894.7M , and -5.8% cumulative change since FY2023) , GAAP net income of -$7.9M, operating cash flow of $83.2M, and free cash flow of $83.2M (+43.0% YoY). On the balance sheet, NEOG closed FY2025 with $3.36B in total assets against $792.9M in total debt (Altman Z-Score: 1.45, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-05-31	$870.4M	-$7.9M	$83.2M	$83.2M	$3.36B	$792.9M
FY2024 (FY)	2025-05-31	$894.7M	-$1.09B	$58.2M	$58.2M	$4.05B	$889.9M
FY2023 (FY)	2024-05-31	$924.2M	-$9.4M	$35.3M	$35.3M	—	—

3. NEOG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NEOG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does NEOG compare to CLDX and NTLA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for NEOG?

Where is NEOG trading relative to its 50-day, 200-day, and 52-week technical levels?

NEOG last traded at $11.82 (0.00% on volume of 2,797,663 shares), positioning the stock -3.43% below its 50-day simple moving average ($12.24) and +13.11% above its 200-day simple moving average ($10.45). Across its 52-week range of $5.37 to $14.26, NEOG sits at the 72.6% percentile with a 14-day RSI of 45.9 (NEUTRAL RANGE) and an implied next-earnings move of ±9.7% ($10.67 to $12.97).

Direct Sub-Reports: NEOG RQD Cockpit NEOG 12M Forecast NEOG Earnings & Move NEOG Dividends & DRIP NEOG Insiders & 13F NEOG Whale Options NEOG Profit Sankey NEOG News & Why

ROARABLE RATING BRIEF • RQD 47/100 (D) ✓ SEC XBRL & RQD VERIFIED

NEOG — Neogen Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2026-05-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Neogen Corporation (NEOG) earns a live Roarable RQD composite score of 47/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $11.82 (0.00% 1D, market capitalization $2.58B).

Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -0.6%, gross margin of 46.9%, operating margin of -2.5%, and free cash flow yield of 3.11%.
Whale 13F & Options Flow (10/20) + Insider Conviction (8/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (12/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of 1.45, Piotroski F-Score of 7/9, and Debt/Equity of 0.38x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Neogen Corporation (NEOG) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry. It carries a market capitalization of $2.7B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2026-05-31), Neogen Corporation (NEOG) reported $870.4M in annual revenue (up from $894.7M in FY2024, -2.7% YoY) and -$7.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($924.2M revenue, -$9.4M net income) through FY2025, NEOG scaled operating cash flow to $83.2M and free cash flow to $83.2M, backed by $3.36B in total assets against $792.9M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D • RQD 47/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 3.11% and institutional whale pillar of 10/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $5.37 – $14.26 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -2.5% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies are therefore — Sector and industry classification (Health Care; In Vitro & In Vivo Diagnostic Substances) is provided, but no sector correlation coefficients or bottleneck mapping are supplied.

Key Question #1: Can NEOG sustain or expand its -2.5% operating margin and -0.6% ROIC against Biotechnology: In Vitro & In Vivo Diagnostic Substances peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $870.4M and free cash flow of $83.2M, how will capital allocation balance growth reinvestment against $792.9M in total debt?
Key Question #3: How sensitive is NEOG's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NEOG Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Neogen Corporation (NEOG) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NEOG Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 22h ago

Neogen stock up 8% on better-than-expected Q1 results, guidance

Yahoo Finance report covering Neogen Corporation (NEOG) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GuruFocus • 1d ago

Neogen Corp (NEOG) Set to Report Q1 Earnings Amid Mixed Valuatio

GuruFocus report covering Neogen Corporation (NEOG) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Neogen Corporation 2027 Q1 - Results - Earnings Call Presentation (NASDAQ:NEOG) 2026-10-10

Seeking Alpha report covering Neogen Corporation (NEOG) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE marketscreener.com • 1d ago

Earnings Flash (NEOG) Neogen Corporation Reports Q1 Revenue $222.8M, vs. FactSet Est of $208.2M

marketscreener.com report covering Neogen Corporation (NEOG) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 1d ago

Why Is Neogen Stock Gaining Thursday?

TradingView report covering Neogen Corporation (NEOG) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE www.debelegger.nl • 1d ago

Neogen (NEOG) Stock Price, Chart & Analysis

www.debelegger.nl report covering Neogen Corporation (NEOG) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Quiver Quantitative • 1d ago

Neogen Reports $222.8 Million Revenue and Raises Fiscal 2027 Guidance

Quiver Quantitative report covering Neogen Corporation (NEOG) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 4d ago

IDEXX Laboratories Reports Soon: How Has The Stock Reacted To Past Earnings?

IDEXX Laboratories (NASDAQ:IDXX) is scheduled to report its earnings on Monday, November 2, 2026. The company has a market value of about $45.5 billion. Over the last twelve months it generated $4.6 billion in revenue an

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NEOG Bull vs. Bear Conversation Board — What's Your Call at $11.82?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NEOG 🐻 33% BEARISH CONVICTION

TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $15.60 (+32.0%)

📌 Pinned Debate

Per the news feed, shares rose 8% on better-than-expected Q1 results and guidance, with Q1 revenue reported at $222.8M against a $208.2

Long NEOG at $11.82 targeting $15.60. Per the news feed, shares rose 8% on better-than-expected Q1 results and guidance, with Q1 revenue reported at $222.8M against a $208.2M estimate.. Institutional whale score is 10/20 and the risk/reward vs. the $5.37 52-week low is skewed heavily in favor of bulls.

SectorRotator 🐂 BULL

@TapeReader_Pro Agree on the RQD 47/100 quality, though with 1.0 beta I'm scaling in with half-size at $11.82 and keeping dry powder in case we test $10.99.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $9.46 (-20.0%)

Spot @ $11.82

Per the RQD rating, ROIC is -0.6% and the Fundamental Cash Engine scores only 7 of 20, with FY 2025 operating income of -$21.6M.

I respect the product at Neogen Corporation, but the stock at $11.82 is a different story. Per the RQD rating, ROIC is -0.6% and the Fundamental Cash Engine scores only 7 of 20, with FY 2025 operating income of -$21.6M.. FCF yield is 3.11% and RQD sits at 47/100 (D) — why pay up here when you can wait for next quarter's numbers?